Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort

Lavender, Brittany; Hooker, Caitlin; Frampton, Chris; Williams, Michael A.; Carson, Simon; Paterson, Aimee; McGregor, Reuben; Moreland, Nicole J.; Gell, Katie; Priddy, Frances; Wiig, Kjesten; Gros, Graham Le; Ussher, James E.; Brewerton, Maia

doi:10.1016/j.vaccine.2023.07.051

Vaccine

2023

DOI: 10.1016/j.vaccine.2023.07.051

|View full text |Cite

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort

Brittany Lavender¹,

Caitlin Hooker²,

Chris Frampton³

et al.

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.

McGregor,

Paterson,

Lavender

et al. 2024

Vaccine

View full text Add to dashboard Cite

The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.

McGregor,

Paterson,

Lavender

et al. 2024

Vaccine

View full text Add to dashboard Cite

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study

Djordjevic,

Matic,

Milovanovic

et al. 2023

Srp Arh Celok Lek

View full text Add to dashboard Cite

Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant predominance in Serbia. Methods. The data for the period from Aug 18th to Oct 1st 2021, were used to estimate the incidence rates of the SARS-CoV-2 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission. The study included 41,186 fully vaccinated subjects, of which 13,589 had received the third dose. VE was estimated based on the incidence rate ratio following vaccination with three versus two doses. Results. We found that a third dose of all investigated vaccines reduces the incidence of both SARS-CoV-2 infection and severe illness that requires hospitalization or ICU admission. The highest VE against infection demonstrated BNT162b2, followed by Gam-COVID-Vac and BBIBP-CorV. Third dose vaccination reduced the risk of hospitalization (incidence rate IR = 0 for Gam-COVID-Vac and BBIBP-CorV), and ICU admission (IR = 0 for all vaccines). The hazard distributions for SARS-CoV-2 infection and hospitalization following vaccination with three versus two doses were significantly different. Conclusion. These findings indicate that an additional, third dose of studied vaccine boosters protection against all investigated outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort

Cited by 2 publications

References 15 publications

The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.

The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study

Contact Info

Product

Resources

About